Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Prospective Cohort Study of Local Recurrence After Radical Breast Cancer Resection

Clinicopathological Characteristics and Prognosis of Local Recurrence After Radical Mastectomy for Breast Cancer: A Prospective Cohort Study

The goal of this observational study is to analyze clinicopathological characteristics and identify independent prognostic risk factors, as well as compare treatment outcomes in female patients aged ≥18 years with pathologically confirmed local recurrence of breast cancer after radical surgery (breast-conserving surgery or total mastectomy) without distant metastasis. The main questions it aims to answer are:

What clinical and pathological factors independently affect progression-free survival (PFS) and overall survival (OS) of breast cancer patients with postoperative local recurrence? Do clinical features and long-term prognosis differ between patients with local recurrence after breast-conserving surgery and those after total mastectomy? Can we identify optimal individualized treatment regimens and suitable populations for re-breast-conserving surgery and postoperative radiotherapy after R0 resection?

Participants will:

Provide complete baseline demographic, initial clinicopathological, primary surgical and adjuvant treatment data, local recurrence lesion characteristics and post-recurrence treatment information via standardized case report forms; Undergo routine clinical examinations, imaging reviews and pathological rechecks as standard clinical practice; Receive standardized follow-up for at least 3 years through outpatient visits supplemented by telephone/WeChat contact to record disease progression, secondary local recurrence, distant metastasis, all-cause death and treatment adverse events.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

This is a single-center, prospective, non-interventional cohort study. It aims to analyze the clinicopathological characteristics of female patients with isolated local recurrence without distant metastasis after radical breast cancer surgery, identify independent prognostic risk factors affecting progression-free survival (PFS) and overall survival (OS), compare the clinical features and long-term prognostic differences between patients with local recurrence after breast-conserving surgery and those after total mastectomy, and explore eligible populations and optimal individualized treatment strategies after local recurrence. Female patients treated at the Department of Breast Surgery, Jiangsu Provincial People's Hospital, aged ≥18 years, pathologically confirmed to have postoperative local breast cancer recurrence without distant metastasis, tolerant to anti-tumor therapy and capable of completing full follow-up will be consecutively enrolled, and all subjects will sign informed consent forms. Baseline demographic data, primary clinicopathological information, initial surgical and adjuvant treatment records, characteristics of recurrent lesions, and comprehensive treatment data after local recurrence will be uniformly collected to establish a standardized electronic database with double-data entry for quality control. Standardized follow-up of at least 3 years will be conducted starting from the date of confirmed local recurrence, mainly through outpatient reexaminations supplemented by telephone and WeChat follow-up. Endpoint events including secondary local recurrence, distant metastasis, all-cause death and treatment-related adverse reactions will be recorded. Statistical analyses will be performed using SPSS 26.0 and R 4.3.0. Kaplan-Meier survival analysis and the Log-rank test will be adopted for univariate prognostic comparison. Multivariate Cox regression and Logistic regression models will be constructed to screen independent influencing factors. Subgroup and interaction analyses will be carried out stratified by initial surgical modality, molecular subtype, recurrence interval and lesion size. A prognostic nomogram prediction model will be developed based on regression models, with its discrimination and calibration validated. This study will not interfere with routine clinical treatment regimens; all patients will receive treatment in accordance with domestic breast cancer guidelines and institutional MDT standards. All research data will be anonymized throughout the study. After follow-up completion, data will be locked uniformly, and multiple imputation and sensitivity analyses will be performed to ensure robust results. The findings of this study can provide prospective evidence for risk stratification, prognostic assessment and the formulation of individualized treatment regimens for breast cancer patients with postoperative local recurrence.

Typ studie

Pozorovací

Zápis (Odhadovaný)

100

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

This single-center prospective observational cohort enrolls female patients aged ≥18 years from the Department of Breast Surgery, Jiangsu Provincial People's Hospital. Eligible participants previously received breast-conserving surgery or total mastectomy for pathologically confirmed invasive breast carcinoma or ductal carcinoma in situ (DCIS), with newly pathologically proven isolated local breast cancer recurrence and no distant metastasis. Subjects must have ECOG performance status 0 or 1 to tolerate salvage reoperation and anti-tumor therapy, and sign written informed consent voluntarily. Patients are excluded if they have concurrent distant metastasis at recurrence, severe cardiac, hepatic, renal or other vital organ dysfunction that prevents treatment, or fail to comply with long-term follow-up.

Popis

Inclusion Criteria:

  1. Patients with a prior history of breast-conserving surgery or total mastectomy, with postoperative pathological diagnosis of invasive breast carcinoma or ductal carcinoma in situ (DCIS);
  2. Pathologically confirmed isolated local recurrence of breast cancer after primary surgery, without evidence of distant metastasis;
  3. Aged ≥ 18 years old; Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and eligible to receive reoperation and subsequent anti-tumor therapy;
  4. Voluntarily participate in this study and provide written informed consent.

Exclusion Criteria:

  1. Presence of concurrent distant metastasis at the time of breast cancer local recurrence;
  2. Severe dysfunction or failure of vital organs (cardiac, hepatic, renal, etc.) that contraindicates reoperation or systemic anti-tumor treatment;
  3. Inability to complete scheduled long-term follow-up as required by the study.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
Breast cancer patients with local recurrence after radical surgery
This cohort includes female patients aged ≥18 with pathologically confirmed isolated local breast cancer recurrence after radical surgery (breast-conserving surgery or total mastectomy) and no distant metastasis, who can tolerate anti-tumor therapy and complete long-term follow-up. This is a non-interventional prospective cohort without experimental interventions; all patients receive standard salvage therapies per national breast cancer guidelines and hospital MDT rules. Treatments of interest are salvage reoperation, postoperative radiotherapy, chemotherapy, endocrine therapy and anti-HER2 targeted therapy for recurrent lesions. Researchers collect full baseline, primary tumor, surgery and recurrence treatment data, and conduct ≥3 years of follow-up to record PFS, OS, secondary local recurrence, distant metastasis and adverse events.
This is a non-interventional prospective cohort study. No experimental treatments are provided by researchers. All therapeutic interventions are standard salvage therapies formulated by the hospital MDT team following official breast cancer guidelines, including salvage reoperation, postoperative radiotherapy, chemotherapy, endocrine therapy and anti-HER2 targeted therapy. The study only retrospectively collects and compares routine clinical treatment data to explore their associations with patients' survival outcomes, and will not adjust or allocate any treatment plans for participants.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Progression-Free Survival (PFS)
Časové okno: At least 3 years of follow-up
Time from confirmed local recurrence to first disease progression (secondary local recurrence, regional lymph node metastasis, distant metastasis) or all-cause death.
At least 3 years of follow-up
Overall Survival (OS)
Časové okno: At least 3 years of follow-up
Time interval from the date of confirmed local breast cancer recurrence to death from any cause.
At least 3 years of follow-up

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Secondary Local Recurrence Rate
Časové okno: At least 3 years of follow-up
Percentage of participants who develop secondary local lesion recurrence during follow-up period.
At least 3 years of follow-up
Distant Metastasis Rate
Časové okno: At least 3 years of follow-up
Percentage of participants who develop systemic distant metastasis during follow-up period.
At least 3 years of follow-up
Incidence of Treatment-Related Adverse Events
Časové okno: At least 3 years of follow-up
Percentage of participants experiencing adverse events during post-recurrence anti-tumor treatment.
At least 3 years of follow-up

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

20. července 2026

Primární dokončení (Odhadovaný)

30. prosince 2031

Dokončení studie (Odhadovaný)

30. prosince 2036

Termíny zápisu do studia

První předloženo

22. června 2026

První předloženo, které splnilo kritéria kontroly kvality

22. června 2026

První zveřejněno (Aktuální)

25. června 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

25. června 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

22. června 2026

Naposledy ověřeno

1. června 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

The individual participant data involves sensitive personal clinical information of patients, and there is no established data sharing protocol approved by the ethics committee for external researchers at present. Therefore, IPD will not be shared after the study is finished.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Rakovina prsu

3
Předplatit